Aurora kinase A (AURKA) is a therapeutic target for GBM, and combination of an AURKA inhibitor and an FAO inhibitor prolonged total survival time in a GBM patient-derived xenograft model [179]. This evidence concerns the gene AURKA and glioblastoma.